Inhibikase Therapeutics Inc IKT

$1.52 -0.01 (-0.65%)

Valuation

Market cap
214,613,000
Revenue TTM
$0
Net income TTM
$-48,260,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
333,100
Avg volume
609,754
Day's range
$1.49 – $1.58
Shares out
140,270,000
Stochastic %K
31%
Beta
0.94
Analysts
Strong Buy
Price target
$5.55

Price

Company profile

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate design...

Show more

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.

Industry
Biotechnology
Sector
Healthcare
Phone
302 295 3800
Website
https://www.inhibikase.com
Address
1000 N. West Street, Suite 1200, Wilmington, United States

Latest news

Stocktwits

GregK13 Nov 6, 6:33 PM
$IKT
0 replies
SannieVerraderlijk Oct 29, 8:30 AM
Bought some shitcos with some of the SLN cash: $PRQR , $IKT , $IRD, doubled $RLMD position
0 replies
GregK13 Oct 29, 12:50 AM
$IKT Analysts love this ticker!
0 replies
jemer Oct 19, 5:01 PM
$IKT I have$50K burning a hole in my pocket that will be buying more IKT shares at $1.50. Sector abuse is way over done. Worst technicals in 5 years now!
1 replies
coder79 Oct 6, 8:15 PM
Healthcare dip-pullback scan (6 Oct) $ALKS $HCSG $CLYM $IKT: all 17–40% off 52W highs, with MACD histogram rising 2+ bars and RSI turning up from the 30s–40s. Entry trigger: buy only on a break above the prior day's high, with volume above average. Stop: below the recent swing low. No trigger, no trade. Dip bought on confirmation, not on a falling knife. 📈 Not financial advice. #swingtrading #healthcare
0 replies
GregK13 Sep 21, 2:59 PM
$IKT ?
0 replies
TJC1791 Sep 12, 2:10 AM
$IKT here’s a comparison of the new corporate deck vs the old one. https://chatgpt.com/share/6aa4b188-e1c4-83ec-aeea-e5b1cf88b03c?ogimg=plain
0 replies
TJC1791 Sep 8, 11:53 PM
$IKT new but I haven’t spotted any changes yet. I’ll look closer later. https://ir.stockpr.com/inhibikase/sec-filings-email/content/0001193125-26-385293/d152999dex991.htm
0 replies